FNY Investment Advisers’s Immunome IMNM Stock Holding History

Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake
Trade Value Portfolio Weight Portfolio Position
2026
Q1
Sell
-50
Closed -$1K 933
2025
Q4
$1K Buy
+50
New +$878 ﹤0.01% 835
2024
Q3
Sell
-4,860
Closed -$58K 732
2024
Q2
$58K Buy
+4,860
New +$76K 0.04% 235
2023
Q3
Sell
-3,500
Closed -$27K 667
2023
Q2
$27K Buy
+3,500
New +$19.1K 0.03% 217

Other funds holding IMNM

FNY Investment Advisers's IMNM Position: Q1 2026 in Review

FNY Investment Advisers sold out of Immunome (IMNM) in Q1 2026, closing a stake of 50 shares — an estimated $1K sold.

FNY Investment Advisers first reported a position in IMNM in Q2 2023 and held it in 3 quarters. The position peaked at $58K in Q2 2024. 201 funds tracked by Wall St. Rank hold IMNM as of Q1 2026.

  • FNY Investment Advisers reported no remaining Immunome position as of Q1 2026 after selling out during the quarter.
  • FNY Investment Advisers sold 50 Immunome shares in Q1 2026, an estimated $1K.
  • FNY Investment Advisers first reported a position in Immunome in Q2 2023 and held it in 3 quarters.
  • FNY Investment Advisers's Immunome position peaked at $58K in Q2 2024.
  • 201 funds tracked by Wall St. Rank held Immunome as of Q1 2026.

Based on FNY Investment Advisers's 13F filing for Q1 2026, filed 15 Apr 2026.